In collaboration with Payame Noor University and Iranian Society of Physiology and Pharmacology

Document Type : Article

Authors

1 Sc. of Biochemistry, Department of Biology, Payamnoor University, Tehran, Iran

2 Professor of Biochemistry Department, Payamnoor University

3 Ph.D. of Biochemistry, University of Georgia

4 M.Sc. of Molecular Biology, Emam Hosein University

5 M.Sc. Student, Genetic Department, Tarbiat Modares University

Abstract

  Abstract
The altered or mutated forms of genes known as proto-oncogenes are responsible for promoting cell growth and uncontrolled cell proliferation. An accumulation of many mutations in different and specific genes,over time is required to cause cancer. The pattern of gene expression, also called molecular signature is unique to a particular class of tumor or tumor cell. This paper describes the latest technique for monitoring the expression of a panel of cancer-specific genes. The PCR technique combines the quantitative performance of SYBR® Green-based real-time PCR is widely used for gene profiling. This technique is cost-effective, easy-to-use, and focuses only on the genes that you desire. In this study the expression of our target genes were quantitatively determined in five human cancer cell lines. We selected gene β-actin as our reference gene. Cells were lysed and the mRNAs were extracted using the RNA Purification Kit and cleaned up with Qiagen RNeasy spin columns. The first-strand cDNA was synthesized according to the High Capacity cDNA Reverse Transcription Kit protocol. RT-PCR were performed with Gene Expression Assays in an AB step one plus Sequence Detection System. Briefly the expression of p53 was high in both breast cancer cell lines, MCF7, T47-D and lung cancer cells, A549. Src expression was higher in prostate cell line, PC3 and lung cancer cells, A549. Meanwhile SKOV3 (ovarian cancer cell line) showed high expression of her-2 gene.  The results clearly show that the expression pattern of this panel of genes was unique to almost every cell line examined.
 

Keywords

Beharry, Z.; Zemskova, M.; Mahajan, S.; Zhang, F.; Ma, J.; Xia, Z.; et al. (2009). Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther; 8: 1473-83.
Browne, BC.; Crown, J.; Venkatesan, N.; Duffy, MJ.; Clynes, M.; Slamon, D.; et al. (2011). Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann Oncol; 22: 68-73.
Iorio, M.V.; et al. (2006). MicroRNA gene expression deregulation in human breast cancer. Cancer Res; 65, 7065-7070 (2005). Nature Rev. Cancer; 6: 857-866,
Joinpoint Regression Program, Version 3.5.2. Bethesda, MD.; (2011). Statistical Research and Applications Branch, National Cancer Institute.
Koboldt, DC.; Fulton, RS.; McLellan, MD.; Schmidt, H.; Kalicki-Veizer, J.; McMichael, JF.; et al. (2012). Comprehensive molecular portraits of human breast tumours. Nature.
Lapointe, J.; et al. (2004). Gene expression profiling identifies clinically relevant subtypes of prostat cancer. Proc. Natl Acad. Sci. USA 101, 811-816.
Mecham, BH.; Klus, GT.; Strovel, J.; Augustus, M.; Byrne, D.; Bozso, P.; et al. Sequence-matched probes.
Online publication date: 1-Aug-2012.
Olff, AC.; Hammond, ME.; Hayes,   DF.; (2012). Re: Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst; 104: 957-958.
Pfaffl, M.W.; (2010). The ongoing evolution of qPCR. Methods; 50: 215-216.
Prat, A.; Parker, JS.; Karginova, O.; Fan, C.; Livasy, C.; Herschkowitz, JI.; et al. (2010). Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res.
Produce increased cross-plat-form consistency and more reproducible biological results in microarray-based gene expression measurements. (2004). Nucleic Acids Res; 32:e74.
Protective effects of liquiritin apioside on cigarette smoke-induced lung epithelial cell injury. Fundamental & Clinical Pharmacology 26: 10.1111/fcp. 2012. 26. issue-4, 473-483.
Rhodes, D.R.; et al. (2005). Mining for regulatory programs in the cancer transcriptome.Nature Genet; 37, 579-583.
Rothenberg, M.E.; et al. (2008). Human and Rat Hepatocytes Cultured on Ultra-Web and Ultra-Web Polyamine Synthetic Matrices show Enhanced Physiologic Activity When Compared to Collagen. Application Note - Corning Life Sciences Technical Monograph CLS-AN-094: Article can be downloaded from Technical Information/ Cell Culture / Culture Surfaces at www.corning.com / lifesciences.-See more at: http://www.sigmaaldrich.com/technical-documents/articles/biofiles/evolution-of-cell.html#sthash.U8TjewtR.dpuf
Sun, Y.; Niu, J.; Huang, J.; (2009). Neuroendocrine differentiation in prostate cancer. Am J Transl Res; 1: 148-162.
Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Mortality-All COD, Aggregated With State, Total US (1969-2009) . Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2012. Released September 2012; underlying mortality data provided by National Center for Health Statistics 2012.
Surveillance Research Program, National Cancer Institute. (2012). SEER*Stat Software, version 7.1.0. Bethesda, MD.
The Analysis of Small Molecule Metabolite Profiles in the Blood as a Biomarker of Lung Cancer, Peter Mazzone et al. (2014). Chest, doi: 10.1378/chest.1989452, published online October.
Wang, W.; Epstein, JI.; (2008). Small cell carcinoma of the prostate: A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol; 32: 65-71.
Wang, SP.; Wang, WL.; Chang, YL.; et al. (2009). p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol; 11: 694-704.
Weinstein, I.B.; Joe, A.K.; (2006). Mechanisms of disease: Oncogene addiction—a rationale for molecular targeting in cancer therapy. Nature Clinical Practice Oncology; 3: 448-457.
Wheeler, DL.; Iida, M.; Dunn, EF.; (2009). The role of Src in solid tumors. Oncologist; 14(7): 667-78. doi:10.1634/theoncologist.2009-0009. PMC 3303596. PMID 19581523.
Ying, M.; Li, D.; Yang, L.; Wang, M.; Wang, N.; Chen, Y.; et al. (2010). Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma. J Cancer Res Clin Oncol.